Connect with us

Technology

In-Licensing Opportunity: How a Pharma Leader Leveraged Scientific Innovation for Clinical and Commercial Success | DelveInsight

Published

1 year ago

on

A leading U.S.-based drug delivery device company known for its strong global commercial presence recognized this opportunity and aimed to expand its portfolio through in-licensing pharma innovation. With an increasing focus on patient-friendly drug administration, the company sought to in-license a dissolvable microneedle technology (dMTS)—a non-invasive platform capable of delivering a variety of drugs and vaccines through a patch format. However, the road to in-licensed products was not without hurdles.

LAS VEGAS, March 24, 2025 /PRNewswire/ — The objective was to assess dissolvable microneedle technology and identify top licensing partner companies with the right technological competencies, clinical capabilities, and commercial readiness using secondary and primary intelligence. The company needed a comprehensive pharma market assessment to evaluate potential partners developing innovative dMTS-based drug delivery systems, ensuring they had the expertise to bring novel concepts from the lab to clinical trials and, ultimately, the market.

Recognizing the situation’s complexity and the advantages of in-licensing and out-licensing, the company turned to DelveInsight, a trusted expert in pharma market intelligence and strategic licensing. Using a combination of secondary and primary intelligence, DelveInsight conducted a deep dive into the pharma in-licensing landscape, identifying the most promising players in the microneedle technology space. The assessment provided the company with a clear roadmap—pinpointing potential partners, evaluating their clinical pipelines, and determining their in-licensing agreement potential.

In the evolving pharmaceutical landscape, bridging the gap between scientific innovation and commercial success is a persistent challenge. Many blockbuster drugs and drug delivery technologies originate from smaller biotech firms or academic research centers, where groundbreaking discoveries happen, but commercial expertise is often lacking. This is where pharma in-licensing becomes a game-changer—allowing large players to acquire cutting-edge innovations and propel them toward clinical development and market success.

Looking for the right in-licensing opportunities? Reach out to us today! Get a tailored proposal and let DelveInsight guide you with expert market intelligence and strategic licensing support.

DelveInsight’s Methodology: A Strategic Approach to In-Licensing dMTS Technology

To help the company identify the right in-licensing opportunity in dissolvable microneedle technology (dMTS), DelveInsight applied a structured, intelligence-driven approach. By leveraging its expertise in pharma licensing services and conducting comprehensive assessments, DelveInsight provided actionable insights that enabled the company to make informed decisions for in-licensing pharma assets.

dMTS Market Assessment: DelveInsight conducted an in-depth pharma market assessment, analyzing the Asia-Pacific landscape for dissolvable microneedle technology and identifying growth trends, key players, and competitive positioning in the in-licensed products space.Company Assessment: DelveInsight evaluated potential licensing partners, assessing their technological capabilities, clinical progress, and commercial readiness to support a successful in-licensing agreement.Technology Assessment: A detailed review of R&D innovations, product pipelines, and formulation technology helped determine the feasibility of in-licensing drugs from top microneedle technology developers.Investment Assessment: DelveInsight analyzed funding patterns, partnerships, and acquisition trends within the dMTS sector, ensuring that potential pharma in-licensing partners had strong financial backing and a robust growth strategy.Primary Assessment: Using primary intelligence, DelveInsight conducted expert interviews, industry surveys, and KOL engagements, validating key findings and gaining deeper insights into the capabilities of potential partners.Strategic Insights on Companies: DelveInsight provided a detailed competitive analysis, highlighting the strengths, weaknesses, opportunities, and risks of various in-licensing opportunities to ensure the client partnered with the most viable company.Assessment of Own Company: By analyzing the client’s existing portfolio, commercial strengths, and expansion goals, DelveInsight identified gaps and strategic areas for growth, ensuring a strong alignment with the selected in-licensing and out-licensing in pharma opportunities.Strategic Goal Building: Finally, DelveInsight helped the company develop a clear roadmap for in-licensing success, outlining potential partnerships, deal structures, and commercialization strategies to drive clinical development and commercial milestone achievement.

Through this intelligence-backed methodology, DelveInsight provided the client with a data-driven, strategic approach to in-licensing, enabling them to secure the right licensing opportunity and expand their footprint in the drug delivery technology market.

Strategic Outcomes with DelveInsight’s Licensing Expertise:

Matrix Analysis identified and positioned the top 20 potential licensing partners based on their technological, clinical, and commercial capabilities.The client gained a clear assessment of the top companies best aligned with their strategic goals and licensing objectives (the TARGET quadrant).DelveInsight facilitated direct meetings with 4-5 high-potential companies, enabling the client to advance in-licensing discussions efficiently.

By leveraging DelveInsight’s expertise, the company successfully secured a high-value in-licensing opportunity, giving a scientific innovation the boost it needed to reach clinical development and commercial milestone achievement. This case underscores the benefits of in-licensing—a strategic approach that enables large pharmaceutical players to stay ahead of the competition by integrating cutting-edge research into their pipelines while ensuring that breakthrough therapies reach the market faster.

Exciting, isn’t it? Don’t just watch innovation happen—secure it! Explore top in-licensing opportunities with our expert guidance.

Regulatory Analysis: DelveInsight’s regulatory intelligence services simplify global approvals by consolidating complex regulatory data into a single platform. With ever-changing guidelines and country-specific requirements, navigating approvals for NCEs, biologics, biosimilars, and cell or gene therapies can be daunting. A single misstep can mean costly delays. Our experts provide clear, comparative insights into global regulatory frameworks, helping clients streamline approvals, mitigate risks, and prioritize markets with faster access.

Portfolio Management: DelveInsight’s Portfolio Management services help clients assess competencies, leverage strengths, and align strategic priorities. Our structured approach identifies market needs, optimizes resources, and enhances portfolio value. With comprehensive market intelligence, we empower organizations to make informed, data-driven decisions, minimizing risks and maximizing long-term impact for both customers and the company.

R&D Analysis: DelveInsight’s skilled research and development analyst specializes in the complexities of different indications, offering essential insights and advice to clients aiming to advance in research and development. They utilize a methodical assessment approach, aligned with industry norms, to track the progress of each drug in both pre-clinical and clinical stages. DelveInsight’s comprehensive reports are crafted to reduce uncertainties and highlight overlooked areas, providing organizations with timely and strategic intelligence.

Why Choose DelveInsight?

DelveInsight’s Licensing Services help pharma companies secure the best in-licensing and out-licensing opportunities by identifying strategic partners and facilitating successful deal-making. With expertise across all therapeutic areas and a vast global network, we provide comprehensive market intelligence, decision-mapping matrix assessments, and expert engagement services to streamline the licensing process. Our approach ensures that clients receive a curated list of potential partners, expert-led discussions, and in-depth strategic insights, making licensing decisions more effective and result-driven. In an industry where the right partnerships drive commercial success, DelveInsight’s systematic methodology ensures seamless negotiations and long-term growth.

Ready to find the perfect licensing partner? Let’s connect!

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform, PharmDelve.

Contact Us
Shruti Thakur
info@delveinsight.com
+14699457679

Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg 

 

View original content:https://www.prnewswire.co.uk/news-releases/in-licensing-opportunity-how-a-pharma-leader-leveraged-scientific-innovation-for-clinical-and-commercial-success–delveinsight-302407772.html

Related Topics:
Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

RTI International Congratulates DOE And Research Teams Advancing The Genesis Mission

Published

8 seconds ago

on

July 23, 2026

By

Highlights:

DOE announced selected research teams supporting the Genesis Mission278 projects selected by DOE to support Genesis Mission objectivesRTI supports the Mission through operation of the Genesis Mission Consortium

RESEARCH TRIANGLE PARK, N.C., July 23, 2026 /PRNewswire/ — RTI International, an independent scientific research institute, congratulates the U.S. Department of Energy and the research teams announced at the Genesis Mission Annual Summit in Washington, D.C. this week. The selections represent an important milestone in advancing the Genesis Mission’s vision for AI-enabled scientific discovery to advance energy, national security and global competitiveness.

The Genesis Mission is a national initiative that aims to double the productivity and impact of American research within a decade. It is designed to unite DOE national laboratories, industry, academia and other partners to harness artificial intelligence for breakthroughs in energy dominance, discovery science and national security. During the summit, DOE announced the selection of 342 participating institutions as award recipients whose projects will contribute to advancing the Genesis Mission’s objectives.

The summit brought together more than 650 participants, including researchers, agency leaders, members of Congress, scientific leaders and industry partners for plenary sessions, showcases and networking opportunities. The event served as a convening point for stakeholders working to advance the Genesis Mission’s vision and strengthen collaboration across the research, technology and innovation communities.

“RTI congratulates DOE and the award recipients announced at the Genesis Mission Annual Summit,” said Tim J. Gabel, president and CEO of RTI. “These recipients exemplify the collaborative spirit at the heart of the Genesis Mission and demonstrate the value of bringing together expertise, capabilities and resources from industry, academia and government to address some of the nation’s most important scientific and technological challenges.”

RTI operates the Genesis Mission Consortium via TechWerx, a DOE partnership intermediary. The consortium provides a mechanism for collaboration among researchers, national laboratories, universities and industry partners supporting the Genesis Mission.

“Through the Genesis Mission Consortium, we are connecting innovators with mission needs, strengthening pathways to adoption and ensuring scientific advances deliver practical benefits for national security. These connections accelerate convergence,” said Senior Director, Consortia Growth and Partnerships at RTI, Ivy Estabrooke, Ph.D.

The consortium brings together organizations from across the AI, computing and scientific research landscape, including cloud providers, AI developers, technology companies, research institutions and national laboratories. Current members include organizations such as Amazon Web Services, Google, IBM, Microsoft, NVIDIA and other leaders from industry and the national laboratory system.

Learn more about the Genesis Mission Consortium

About RTI International

RTI International is an independent scientific research institute dedicated to improving the human condition. Our vision is to address the world’s most critical problems with technical and science-based solutions in pursuit of a better future. Clients rely on us to answer questions that demand an objective and multidisciplinary approach—one that integrates expertise across social, statistical, data, and laboratory sciences, engineering, and other technical disciplines to solve the world’s most challenging problems. For more information, visit www.rti.org.

About TechWerx
TechWerx is a DOE supported innovation hub managed by RTI International through a Partnership Intermediary Agreement. The hub is dedicated to driving collaboration across the energy and national security ecosystems to accelerate the transition and impact of energy-focused science and technology solutions, ultimately enhancing America’s economic and energy security landscape. For more information visit, www.techwerx.org.

Media Contact:
RTI International
9195417300
419371@email4pr.com

View original content:https://www.prnewswire.com/news-releases/rti-international-congratulates-doe-and-research-teams-advancing-the-genesis-mission-302833017.html

SOURCE RTI International

Continue Reading

Technology

Linnworks Releases “Inside Peak” Report, Analyzing Peak Season Preparation Timelines

Published

17 seconds ago

on

July 23, 2026

By

New Data Reveals Peak Prep is Complete as Early as October, Tools and Catalogs Set Well Before Q4 Surge

LOUISVILLE, Ky., July 23, 2026 /PRNewswire/ — Linnworks, a leading provider of e-commerce inventory and order management software, today released Inside Peak, a new report that maps out when top-performing online sellers prepare for the Holiday peak and Black Friday rush.

“Peak is won in the weeks and months before Black Friday, not during it,” said Diana Nolting, Chief Product Officer, Linnworks. “Our data shows a clear, repeatable pattern: the sellers who come out ahead have their tools and catalogs locked in by October. A channel you’re still figuring out in November is a channel working against you when it matters most.”

Analyzing 207.2 million orders placed across 2025, worth $11.88 billion (£8.82 billion) in sales, alongside prep-behavior data spanning 2022 to 2025, the report gives retailers a benchmark to measure their own peak readiness against.

Evaluating order volume, sales value, and prep signals such as new tool integrations and catalog expansion from a subset of Linnworks’ global customers, the report identifies a consistent readiness window. Key findings include:

Demand Piles Into Q4: Q4 takes nearly a third of the year’s orders and 30.9% of its value ($3.68bn/£2.73bn), cresting at Black Friday. Order volume spikes while average basket size holds steady, even dipping slightly during the Black Friday and Christmas weeks, putting the pressure squarely on operations rather than order size.Tooling Decisions Happen Early: New integrations peak in October, nearly a fifth above the monthly average, then fall away sharply in November, as most sellers stop making changes and run on what they set up earlier in the year.Catalogs Expand Ahead of the Rush: Sellers add more new products to their catalogs in October than in any other month, finishing the listings they want live for peak well before the season begins.Channel Mix Multiplies Complexity: Average basket size ranges from about $17.50 (£13) on Temu to about $94.30 (£70) on Shopify, with Amazon’s high-volume orders near ($35) £26. Every channel shares the same Q4 timing, meaning sellers on more channels must meet more sets of expectations at full volume, in the same few weeks.Lead Time Is the Hidden Constraint: New tools take an average of 40 days to go live and settle, so sellers weighing an operational change close to peak are already working against the clock.

The report also features a self-assessment created to evaluate readiness for peak season. The full report is available to download here.

To learn more about Linnworks and its product offerings, please visit Linnworks.com.

About Linnworks
Linnworks is a Connected CommerceOps platform that gives 4000+ online retailers the power to connect, automate, and scale their e-commerce operations from a single source of truth. Our solution brings three core attributes to the retailer: connectivity to 100-plus marketplaces, automation to traditionally time-consuming e-commerce processes, and a centralized platform to manage listings, inventory, orders, and shipments.

Media Contact
Danna Tabachnik
419356@email4pr.com
(773) 453-2444

View original content to download multimedia:https://www.prnewswire.com/news-releases/linnworks-releases-inside-peak-report-analyzing-peak-season-preparation-timelines-302832990.html

SOURCE Linnworks

Continue Reading

Technology

Fraction Becomes DevHawk, Launching an AI Software Factory Companies Can Run Themselves or Hand Off Entirely

Published

22 seconds ago

on

July 23, 2026

By

More than a name change: the launch marks the company’s evolution from fractional engineering into a suite of specialized AI agents, directed by senior engineers, that build, run, and maintain software. DevHawk delivers it two ways, with deep experience across a range of industries.

ATLANTA, July 23, 2026 /PRNewswire/ — Fraction, which since 2022 has given 175 companies access to senior US engineers without the cost of building a team, today announced it has evolved into DevHawk, an AI software factory: a suite of specialist AI agents, directed by senior engineers, that build, run, and evolve the software a business depends on. Companies can have DevHawk operate the factory for them, or run the agents with their own team.

“We built Fraction on a belief I’ve bet my whole career on: leverage beats headcount,” said Praveen Ghanta, Founder and CEO of DevHawk. “Small, senior teams with the right tools outbuild big ones, and they grow profitably instead of bloating the org chart. It’s how I built and sold my last company. Same belief now, with a much bigger engine.”

The agents cover the full engineering lifecycle, spanning up to nine disciplines from product and architecture to QA, DevOps, and security. They don’t just write code; they test it, ship it, and keep it running in production. A single senior engineer directing the suite can do work that once required six to ten people, shipping up to 10x faster and at 80-90% less than a traditional team.

DevHawk offers firms two paths, and positions itself as a partner in both. In the managed model, DevHawk’s senior engineers operate the software factory on the client’s behalf. In the self-serve model, a company adds the agents it needs to its own team and runs them, with DevHawk handling onboarding, integration, and ongoing support.

“It’s the best engineers in the game, 10x’d by a suite of specialized AI agents,” said Ghanta. “Run it with us, or we customize the agents and then you run them yourself.”

Since launching the software factory, DevHawk has seen a sharp uptick in demand from traditionally non-technical industries, including construction, logistics, and healthcare. Its deepest roots are in wealth management and fintech, where getting software wrong is not an option. As off-the-shelf tools stop fitting how these businesses run, more are choosing to own their own software rather than keep renting something that doesn’t fit.

“For the first time, every company can afford software built exactly for how they work,” said Ghanta, “instead of bending their business around off-the-shelf tools.”

About DevHawk
DevHawk (formerly Fraction) is an AI software factory. The company helps businesses build, run, and maintain the software they depend on using a suite of specialized AI agents, run by the company’s own team or operated by DevHawk. DevHawk was founded by Praveen Ghanta, a multiple-time founder who previously built and sold the wealth-technology platform HiddenLevers to Orion. Founded as Fraction in 2022 and headquartered in Atlanta, the company has served more than 175 companies across dozens of industries. Learn more at https://www.devhawk.ai.

Media Contact
Ali Murphy • 419374@email4pr.com • 404.343.7747

View original content to download multimedia:https://www.prnewswire.com/news-releases/fraction-becomes-devhawk-launching-an-ai-software-factory-companies-can-run-themselves-or-hand-off-entirely-302833012.html

SOURCE DevHawk

Continue Reading

Trending